Skip to main content
Erschienen in: Infectious Diseases and Therapy 3/2016

Open Access 26.08.2016 | Erratum

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

verfasst von: Daniel H. Deck, Jennifer M. Jordan, Thomas L. Holland, Weihong Fan, Matthew A. Wikler, Katherine A. Sulham, G. Ralph Corey

Erschienen in: Infectious Diseases and Therapy | Ausgabe 3/2016

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found under doi:10.​1007/​s40121-016-0119-9.

Erratum to: Infect Dis Ther (2016) DOI 10.1007/s40121-016-0119-9

Following publication of the aforementioned article, the authors noted a minor error in Table 1 and two small errors in Table 2. In Table 1, the Eron Class III Clinical Criteria should read CrCl <30 mL/min or on dialysis, not CrCl <20 mL/min. In Table 2, Distribution of SOLO patients in modified Eron Classes I–III, the number of outpatients receiving vancomycin (VAN) in Class I should be 111, not 11. The total number of inpatients (Class I–III) was omitted, n = 1143 (59.8%).
Table 1
Clinical criteria used to define modified Eron Classes I–IV
Eron class
Clinical criteria
IV
Bacteremia (positive blood culture); or
Absolute total neutrophils count <500
III
Meeting SIRS criteria
CrCl <30 mL/min or on dialysis
ALT/AST >10-times ULN
Heart rate >90/min, breath rate >20/min, or systolic BP <90 mmHg; or
Cancer
II
Age ≥75 years old
Glucose >11.1 mmol/L
Congestive heart failure at the randomization
30 mL/min < CrCl <60 mL/min
Hepatitis (excluding AST/ALT >10-times ULN)
Peripheral vascular disease
Diabetes mellitus
Fever (temperature >38.0 °C); or
BMI ≥30 kg/m2
I
For the patients who didn’t meet Classes II–IV
ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, BP blood pressure, CrCl creatinine clearance, SIRS systemic inflammatory response syndrome, ULN upper limit of normal
Table 2
Distribution of SOLO patients in modified Eron Classes I–III (mITT population, n = 1959)
 
Class I
Class II
Class III
Total (Class I–III)
SOLO mITT (n = 1959)
520 (26.5%)
790 (40.3%)
600 (30.6%)
1910
Inpatients, n (%)
301 (57.9%)
431 (54.6%)
411 (68.5%)
1143 (59.8%)
ORI, n
144
224
203
571
VAN, n
157
207
208
572
Outpatients, n (%)
219 (42.1%)
359 (45.4%)
189 (31.5%)
767 (40.2%)
ORI, n
108
182
89
379
VAN, n
111
177
100
388
mITT modified intent-to-treat, ORI oritavancin, VAN vancomycin

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
verfasst von
Daniel H. Deck
Jennifer M. Jordan
Thomas L. Holland
Weihong Fan
Matthew A. Wikler
Katherine A. Sulham
G. Ralph Corey
Publikationsdatum
26.08.2016
Verlag
Springer Healthcare
Erschienen in
Infectious Diseases and Therapy / Ausgabe 3/2016
Print ISSN: 2193-8229
Elektronische ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-016-0127-9

Weitere Artikel der Ausgabe 3/2016

Infectious Diseases and Therapy 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.